TGA Public Consultation - Dual labelling transition to sole medicine ingredient names

The Therapeutic Goods Administration (TGA) has opened  a public consultation on International harmonisation of ingredient names (IHIN) - Dual labelling transition to sole medicine ingredient names.   

The consultation seeks views on medicine ingredient names that must be displayed as both the old and new ingredient name ('dual labelled') on labels and Product Information (PI) and Consumer Medicine Information (CMI) documents until 30 April 2023 as part of IHIN.  

Have your say 

We are seeking feedback on: 

• whether health professionals, consumers and health systems are ready for dual labelling to end for all ingredient names currently required to be dual labelled
• a proposal to transition medicine labels and PI/CMI documents to sole medicine ingredient names in a certain time frame. 

How you can provide feedback 

Members are welcome to make individual responses to this consultation.  You can view the public consultation at International harmonisation of ingredient names (IHIN) - Dual labelling transition to sole medicine ingredient names on the TGA Consultation Hub.  There is an ‘Online Survey’ button towards the bottom of the consultation page.   

The public consultation will remain open until 19 December 2022.